China, Zai Lab and Vyvgart Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...
Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global ...
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...
VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback